Skip to main content
AmigoFish

Pharmaceutical Executive

Pharmaceutical Executive PodcastAudio

Format:
Podcast
New episodes:
Daily
Typical length:
about 3 minutes
Latest episode:
Not rated yet

About this show

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com (http://PharmExec.com) to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Covers: pharmaceutical industry, drug regulation, pharma business, drug approvals, clinical trials, pharmaceutical dealmaking, obesity drugs, oncology drugs, pharma commercial strategy

Show details and episodes come from the publisher's public feed at audioboom.com. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

This podcast features in-depth interviews with pharmaceutical industry leaders on commercial trends, major conferences and key issues in the sector. Recent episodes cover FDA approvals, Ossium Health's deceased-donor bone marrow bank, Moderna's growth plan and argenx's acquisition of Unnatural Products.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Science shows

Explore more

Episodes

  • Pharmaceutical Executive Daily: Hansoh Pharma Enters Collaboration and License Agreement with Roche for Broad Portfolio of ADCs

    · 2 min

    Merck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe.

    Not rated yet
  • Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology

    · 2 min

    Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.

    Not rated yet
  • Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche

    · 2 min

    Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.

    Not rated yet
  • Pharmaceutical Executive Daily: Thomas Appio Named Interim CEO of Bausch + Lomb

    · 2 min

    Bausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services, and a LogiPharma 2026 conversation makes the case against waiting for perfect data to deploy AI in pharma supply chains.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Tecentriq

    · 2 min

    The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.

    Not rated yet
  • Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

    · 2 min

    Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab

    · 2 min

    Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.

    Not rated yet
  • Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like

    · 3 min

    Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.

    Not rated yet
  • AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?

    · 27 min

    Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Pharm Exec podcast, Matt Walz, CEO of Trialbee, a patient recruitment company, joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how AI is enhancing medical screening, clinical workflows, and enrollment planning. The conversation explores the need for clearer regulatory expectations, human oversight, and workforce training — and why predicting enrollment costs and timelines, Walz believes, could offer one of AI’s most consequential opportunities in clinical trials. Walz also shares how Trialbee is deploying AI on both the patient-facing and operational sides of its business and explains how conversational tools are helping teams move from the world of dashboards to more specific answers.

    Not rated yet
  • Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership

    · 3 min

    Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.

    Not rated yet
  • Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

    · 3 min

    Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos

    · 2 min

    Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.

    Not rated yet
  • Pharmaceutical Executive Daily: Peptide Ruling Stalls

    · 2 min

    Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.

    Not rated yet
  • A Leadership Call to Action for Biotech

    · 35 min

    In this episode of Leading Edge with Ken Banta, Jeremy Levin, D.Phil, MB BChir, co-founder and executive chairman of Ovid Therapeutics, joins Banta, The Vanguard Network founder and CEO, for a wide-ranging and candid discussion on the challenges confronting the U.S. biotechnology industry and the leadership required to strengthen its future. Drawing from Levin’s book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, the prominent and outspoken biopharma leader argues that biotechnology is facing pressures that extend well beyond the traditional cycles of capital and investment. The conversation with Banta and Pharmaceutical Executive's Mike Christel turns squarely to leadership and the industry's relationship with the public. Levin challenges pharma and biotech executives to communicate more clearly what their organizations contribute to patients and society — but stresses that communication must be backed by meaningful action. "Mission without method is a waste of time,” he asserts. Banta and Levin also explore the responsibility of corporate boards, how executive incentives can shape organizational priorities and whether the traditional emphasis on shareholder value adequately reflects the broader societal obligations of healthcare companies.

    Not rated yet
  • Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

    · 3 min

    New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.

    Not rated yet
  • Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

    · 3 min

    Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima

    · 3 min

    FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Onswik

    · 2 min

    InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.

    Not rated yet
  • Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares

    · 3 min

    EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.

    Not rated yet
  • Pharmaceutical Executive Daily: Nine European Drugmakers Note Concern Over Region's Pharma Investments

    · 2 min

    Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.

    Not rated yet